Biotech Co. Hit With Investor Suits Over Cancer Drug Launch
By Sydney Price · May 16, 2025, 9:38 PM EDT
Cancer treatment company Iovance Biotherapeutics has been hit with two proposed shareholder class actions accusing the company of misleading the public about the success of its commercial rollout of an FDA-approved...
To view the full article, register now.